The Prostate Cancer Charity comments on new research, presented
as an abstract at the American Association for Cancer Research
conference, in which a US team have trialled a potential new
treatment for prostate cancer in patients for the first time.
Dr Kate Holmes, Head of Research at The Prostate Cancer Charity,
explains: "This very early stage research, conducted in a small
group of men, indicates that galeterone shows potential as a new
treatment for men with advanced prostate cancer. This new drug is
in its infancy and full results have yet to be published, meaning
that is simply too soon to tell whether or not this drug is capable
of living up to its early promise.
Men in the final stages of prostate cancer have very few options
available to them and we desperately need to increase the number of
effective treatments for these men. The researchers have plans to
test the drug in a further trial, to fully investigate the full
side effects and safety of treatment. We look forward to reading
the full publication of this study in due course, and await with
anticipation the results of further trials."